Healthcare Industry News: CoreValve
News Release - September 8, 2008
CoreValve Announces Successful Completion of Initial Series of Proctored Cases in Australia and New Zealand Using Its ReValving(R) System for Percutaneous Aortic Valve ReplacementCoreValve to present clinical data at "22nd EACTS Annual Meeting" in Lisbon, Portugal
IRVINE, Calif.--(HSMN NewsFeed)--CoreValve (www.CoreValve.com) announced today that five (5) clinical evaluation sites—two in New Zealand and three in Australia—have now completed their first series of proctored cases using the Company’s proprietary ReValving® System for percutaneous aortic valve replacement (PAVR), which features a porcine pericardium valve mounted in a self-expanding frame.
“We are gratified to see tremendous enthusiasm for our ReValving technology in Australia and New Zealand,” said Daniel Lemaitre, President and Chief Executive Officer of CoreValve. “More importantly, the clinical results generated by these pioneering centers are remarkable and a testimony to the ability to leverage the extensive European clinical experience that has catapulted us into the leadership position in the transfemoral aortic valve replacement market.”
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving® System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company’s Web site at www.CoreValve.com.
(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.